SS-31 (elamipretide) , a mitochondria-targeted peptide that stabilizes cardiolipin to support energy production, became the first FDA-approved mitochondrial therapeutic in 2025, though only for the rare Barth syndrome, with the brain rationale still mechanistic and no cognitive trials
These injections are initially used daily, but the frequency is decreased over time once optimal HGH levels are reached
Double Strength of Body Protection Compound
This mix has become the gold standard in growth hormone secretagogue research due to its potent effects on GH rise, clean pharmacology with minimal side effects, maintenance of natural pulsatile GH patterns, and full benefits for body makeup, healing, and anti-aging
Some of which may adversely affect a growing fetus
Science (2013) 339(6123):10848